Report cover image

Critical Assessment of Trump Administration’s Renewed Efforts to Introduce IRP in the US via the MFN Executive Order

Publisher GlobalData
Published Jun 30, 2025
Length 13 Pages
SKU # GBDT20830667

Description

Critical Assessment of Trump Administration’s Renewed Efforts to Introduce IRP in the US via the MFN Executive Order

Summary

In May 2025, US President Donald Trump issued an executive order (EO) stating that pharmaceutical companies should provide Most Favored Nation (MFN) prices to American consumers or face steep penalties. The EO calls for the introduction of International Reference Pricing (IRP) in the US. Based on extensive knowledge of IRP and detailed IRP 360 profiles for 75 markets, in this report GlobalData examines the implications of IRP use by the US for pharmaceutical companies, for payers, and for patient access to medicines in the US itself and in other countries.

Table of Contents

13 Pages
    • Trump Administration Announces Plans to Introduce IRP through MFN EO
    • Subsequent HHS Action Reveals Limited Additional Details About Proposed IRP System
    • Current IRP Plan Is Much Riskier for Pharma than the Two IRP Proposals from Trump's First Term
    • MFN Order Assessed in Light of International IRP Practices and Best Practice Guidelines for Use of IRP
    • Adverse Effects of US Use of IRP for Payers and Patients
    • Adverse Effects of US Use of IRP for the Pharma Industry
    • What Else Can the Pharma Industry Do to Reduce Negative Impact of US IRP Introduction?
    • Outlook and Implications

Search Inside Report

How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.